Ajanta Pharma, a Mumbai-based drug maker, has announced a 4% year-on-year increase in consolidated profit after tax to ₹255 crore for the quarter ended June 30, 2025. This growth was driven by strong sales of branded generics. In comparison, the company had reported a profit after tax of ₹246 crore in the same quarter of the previous fiscal year.
Revenue from operations also saw a significant uptick, reaching Rs 1,303 crore compared to ₹1,145 crore in the corresponding period last year. Ajanta Pharma’s sales of branded generics in India, Asia, and Africa rose by 9% year-on-year to ₹941 crore in the April-June quarter of the current fiscal year. Additionally, sales of generics in the US market surged to Rs 310 crore in the June quarter, marking a 36% growth from ₹228 crore in the previous year. This positive financial performance highlights the company’s strong market position and growth trajectory in the pharmaceutical industry.
Read more from thehindubusinessline.com